Pfizer takes Johnson & Johnson to court for its anticompetitive actions regarding the Ramicade drug

Date: 2017-09-22   Author: Shikha Sinha  Category: #news

Pfizer takes Johnson & Johnson to court for its anticompetitive actions regarding the Ramicade drug

Two of the most globally reputed pharma companies, Pfizer and Johnson & Johnson are squaring off a new front in their legal battles over a rheumatoid arthritis drug.

According to reports, the world’s largest drugmaker, Pfizer, is suing Johnson & Johnson for implementing illegal anti-competitive practices to thwart its cheaper biosimilar of a powerful rheumatoid arthritis drug called Inflectra, launched in late 2016.  Sources revealed that the monopolistic actions of J&J have blocked over 70% of patients from having access to Pfizer’s copycat drug.

The brawl between Johnson & Johnson’s Remicade – the best-selling medicine by far and Pfizer’s biosimilar Inflectra has opened doors to another legal battle in the global biologics and biosimilars market, which, for the record, witnesses numerous legal encounters regarding costs, patents covering the drug, and other competitive barriers.

In this lawsuit filed by Pfizer, the company accused J&J for its anticompetitive actions that denied access to Pfizer’s biosimilar in the US market. It further undermined the company for lowering its drug prices and blocking Pfizer’s biosimilars from entering into the market, on purpose. For the record, biosimilars are intended to be a lower cost alternative and not the exact copy of the expensive drugs. Pfizer further claims that J&J made a deliberate attempt to suppress the competition in an aim to maintain its own monopoly for Remicade. In essence, Pfizer suspects J&J for violating the principal goals of the Federal Biologics Price Competition and Innovation Act.

Meanwhile, Johnson & Johnson has been selling Remicade for last two decades and it carries a sticker price of approximately USD 26,000 per annum for a typical user. While, on other hand, Pfizer’s Inflectra costs around USD 21,000 marking as much as a 40% discount. In the lawsuit, Pfizer has also mentioned that even with the discount, Remicade accounts for 96% of the overall market and generated USD 4.8 billion in US sales, because of J&J’s contracts between health insurers, hospitals, and clinics.

On the contrary, Johnson and Johnson dismissed the lawsuit filed by Pfizer, stating that it had no merit and the allegations are baseless. The president of Janssen Biotech, a division of J&J, further revealed that they are competing on value & price, and it is the fierce competition that is bringing down the overall cost of Remicade and not its anticompetitive behavior.



About Author


Shikha Sinha linkdin-boxtwitter

Shikha Sinha

Shikha currently manages the content team at AlgosOnline. An electrical & electronics engineer by education, she has prior experience in content & technology writing, content marketing, market research, and business development domains. Her other interests inc...

Read More

Post Recommendents

Chrysanthemum Extract Market Size, Demand, Growth, Trends, Segmentation and Forecasts Research to 2026

Author: Ashwin Naphade

Chrysanthemum Extract market report thoroughly expounds on the contingencies created by Covid-19 pandemic in micro-market across regions, and how this governs the overall growth matrix.

The report on Chrysanthemum Extract market provides a...


Chamaemelum Nobile Extract Market to Witness an Outstanding Growth During 2021- 2026

Author: Ashwin Naphade

Chamaemelum Nobile Extract market aims to decode lucrative investment opportunities in the business sphere and educate readers about the bottlenecks created by Covid-19 pandemic.

The report on Chamaemelum Nobile Extract market provides a c...


Chamomilla Recutita Extract Market Insights and In-Depth Analysis 2021-2026 with Types, Products and Key Players

Author: Ashwin Naphade

Chamomilla Recutita Extract market report provides in-depth information about growth catalysts, profitable prospects, restraints, and Covid-19 impact which will influence the growth rate through 2026.

The report on Chamomilla Recutita Extra...